HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Federico Garrido Selected Research

Histocompatibility Antigens Class I

10/2010The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions.
7/2010"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
11/2008Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
8/2008Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.
1/2007Role of altered expression of HLA class I molecules in cancer progression.
1/2007Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
1/2007MHC class I antigens and immune surveillance in transformed cells.
2/2005Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Federico Garrido Research Topics

Disease

40Neoplasms (Cancer)
01/2014 - 02/2002
14Melanoma (Melanoma, Malignant)
01/2014 - 02/2003
9Neoplasm Metastasis (Metastasis)
07/2012 - 09/2003
5Renal Cell Carcinoma (Grawitz Tumor)
01/2013 - 08/2007
4Colorectal Neoplasms (Colorectal Cancer)
09/2012 - 02/2005
4Fibrosarcoma
09/2011 - 05/2004
4Carcinoma (Carcinomatosis)
06/2011 - 09/2002
2Urinary Bladder Neoplasms (Bladder Cancer)
08/2011 - 02/2005
2Kidney Neoplasms (Kidney Cancer)
03/2010 - 08/2007
2Inflammation
03/2010 - 08/2007
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
06/2013
1Autoimmune Diseases (Autoimmune Disease)
07/2012
1Microsatellite Instability
06/2011
1Genomic Instability
06/2011
1Lung Neoplasms (Lung Cancer)
01/2008
1Adenocarcinoma
01/2008
1Stomach Neoplasms (Stomach Cancer)
01/2008
1Clear Cell Adenocarcinoma
01/2008
1Prostatic Neoplasms (Prostate Cancer)
01/2008
1Colonic Neoplasms (Colon Cancer)
08/2007
1Leukemia
01/2006
1Neuroblastoma
04/2005
1Pleural Effusion (Pleural Effusions)
03/2003

Drug/Important Bio-Agent (IBA)

10AntigensIBA
01/2014 - 02/2002
8Histocompatibility Antigens Class IIBA
10/2010 - 02/2005
6CytokinesIBA
07/2010 - 07/2006
5I-antigenIBA
05/2008 - 03/2003
4PeptidesIBA
09/2012 - 06/2003
4DNA (Deoxyribonucleic Acid)IBA
08/2007 - 09/2002
4Messenger RNA (mRNA)IBA
05/2007 - 09/2003
3N-methylsuccinimideIBA
09/2012 - 06/2011
3HLA-A Antigens (HLA-A)IBA
07/2012 - 02/2003
3ChemokinesIBA
06/2011 - 01/2007
3tapasinIBA
02/2005 - 09/2003
2InterferonsIBA
07/2012 - 01/2008
2krestin (PSK)IBA
09/2011 - 01/2008
2Neoplasm Antigens (Tumor Antigens)IBA
10/2010 - 06/2003
2Interleukin-10 (Interleukin 10)IBA
01/2009 - 08/2007
2InterleukinsIBA
01/2009 - 08/2007
2Cancer VaccinesIBA
11/2008 - 01/2007
2HLA-B44IBA
02/2005 - 10/2003
2HLA-B Antigens (HLA-B)IBA
10/2004 - 02/2003
1Codon (Codons)IBA
01/2014
1imatinib (Gleevec)FDA Link
06/2013
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2013
1Clear-cell metastatic renal cell carcinomaIBA
01/2013
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2013
1HLA-DR Antigens (HLA-DR)IBA
07/2012
1Calcibiotic Root Canal SealerIBA
06/2012
1Cyclin A1IBA
03/2012
1docetaxel (Taxotere)FDA Link
09/2011
1Mitomycin (Mitomycin-C)FDA LinkGeneric
08/2011
1Galectin 3 (LGALS3)IBA
06/2011
1Interleukin-2 (IL2)IBA
07/2010
1Interferon-alpha (Interferon Alfa)FDA Link
07/2010
1Interleukin-18 (Interleukin 18)IBA
03/2010
1Immunologic Factors (Immunomodulators)IBA
11/2008
1streptococcal polysaccharide type III group BIBA
01/2008
1Histocompatibility Antigens (Histocompatibility Antigen)IBA
01/2008
1Chemokine CCL5IBA
01/2008
1Proteins (Proteins, Gene)IBA
08/2007
1Interleukin-4 (Interleukin 4)IBA
08/2007
1A-factor (Streptomyces)IBA
01/2007
1Bromodeoxyuridine (BrdU)IBA
01/2006
1Chemokine ReceptorsIBA
09/2005
1Histocompatibility Antigens Class IIIBA
04/2005
1AntibodiesIBA
04/2005
1HLA-G antigen (HLA G)IBA
10/2004
1HLA-C Antigens (HLA-C)IBA
10/2004
1Reactive Oxygen Species (Oxygen Radicals)IBA
05/2004
1Glutathione (Reduced Glutathione)IBA
05/2004
1MethylcholanthreneIBA
05/2004
1Monoclonal AntibodiesIBA
10/2003
1CalnexinIBA
09/2003
1HLA Antigens (Human Leukocyte Antigens)IBA
06/2003
1Complementary DNA (cDNA)IBA
03/2003
1HLA-A1 Antigen (HLA A1 Antigen)IBA
02/2003
1Surface Antigens (Surface Antigen)IBA
02/2002

Therapy/Procedure

17Immunotherapy
01/2014 - 02/2002
3Drug Therapy (Chemotherapy)
09/2011 - 05/2004
2Transplants (Transplant)
07/2012 - 01/2008
2Heterologous Transplantation (Xenotransplantation)
01/2010 - 11/2007
1Homologous Transplantation (Allograft)
07/2012
1Aftercare (After-Treatment)
09/2011
1Antineoplastic Protocols
10/2010
1Transplantation (Transplant Recipients)
01/2008
1Nephrectomy
01/2008
1Oral Administration
01/2006
1Intraperitoneal Injections
01/2006
1Lasers (Laser)
01/2006